BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

417 related articles for article (PubMed ID: 25550930)

  • 21. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects.
    Ampuero J; Aller R; Gallego-Durán R; Crespo J; Abad J; González-Rodríguez Á; Gómez-Camarero J; Caballería J; Lo Iacono O; Ibañez L; García-Samaniego J; Martín-Mateos R; Francés R; Fernández-Rodríguez C; Diago M; Soriano G; Andrade RJ; Latorre R; Jorquera F; Morillas RM; Escudero D; Estévez P; Hernández-Guerra M; Augustín S; Pareja-Megia MJ; Banales JM; Aspichueta P; Benlloch S; Rosales JM; Salmerón J; Turnes J; Romero-Gómez M;
    Liver Int; 2021 Sep; 41(9):2076-2086. PubMed ID: 33896100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The promising role of CCL2 as a noninvasive marker for nonalcoholic steatohepatitis diagnosis in Egyptian populations.
    Ali AA; Fouda A; Abdelaziz ES; Abdelkawy K; Ahmed MH
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e954-e960. PubMed ID: 34907983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Poor Inter-test Reliability Between CK18 Kits as a Biomarker of NASH.
    Pimentel CF; Jiang ZG; Otsubo T; Feldbrügge L; Challies TL; Nasser I; Robson S; Afdhal N; Lai M
    Dig Dis Sci; 2016 Mar; 61(3):905-12. PubMed ID: 26462489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels in patients with biopsy-proven nonalcoholic fatty liver disease.
    Ozturk O; Colak Y; Senates E; Yilmaz Y; Ulasoglu C; Doganay L; Ozkanli S; Oltulu YM; Coskunpinar E; Tuncer I
    World J Gastroenterol; 2015 Jul; 21(26):8096-102. PubMed ID: 26185381
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Natural History of Simple Steatosis or Nonalcoholic Fatty Liver.
    De A; Duseja A
    J Clin Exp Hepatol; 2020; 10(3):255-262. PubMed ID: 32405182
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-Density Lipoprotein (LDL)-Triglyceride and Its Ratio to LDL-Cholesterol as Diagnostic Biomarkers for Nonalcoholic Steatohepatitis.
    Fujii Y; Nouso K; Matsushita H; Kariyama K; Sakurai T; Takahashi Y; Chiba H; Hui SP; Ito Y; Ohta M; Okada H
    J Appl Lab Med; 2020 Nov; 5(6):1206-1215. PubMed ID: 32674154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The potential of soluble CD14 in discriminating nonalcoholic steatohepatitis from nonalcoholic fatty liver disease.
    Nakamura A; Yamamoto K; Takeda R; Yamada R; Kubo A; Morikawa K; Ando S; Shimazaki T; Izumi T; Umemura M; Kitagataya T; Shigesawa T; Suzuki K; Kimura M; Nakai M; Sho T; Suda G; Natsuizaka M; Ogawa K; Ohnishi S; Sugiyama T; Takeda H; Sakamoto N
    Hepatol Res; 2022 Jun; 52(6):508-521. PubMed ID: 35129841
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals.
    Suppli MP; Rigbolt KTG; Veidal SS; Heebøll S; Eriksen PL; Demant M; Bagger JI; Nielsen JC; Oró D; Thrane SW; Lund A; Strandberg C; Kønig MJ; Vilsbøll T; Vrang N; Thomsen KL; Grønbæk H; Jelsing J; Hansen HH; Knop FK
    Am J Physiol Gastrointest Liver Physiol; 2019 Apr; 316(4):G462-G472. PubMed ID: 30653341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Polyunsaturated fatty acid metabolites as novel lipidomic biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis.
    Loomba R; Quehenberger O; Armando A; Dennis EA
    J Lipid Res; 2015 Jan; 56(1):185-92. PubMed ID: 25404585
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cytokeratin 18 fragment levels as a noninvasive biomarker for nonalcoholic steatohepatitis in bariatric surgery patients.
    Diab DL; Yerian L; Schauer P; Kashyap SR; Lopez R; Hazen SL; Feldstein AE
    Clin Gastroenterol Hepatol; 2008 Nov; 6(11):1249-54. PubMed ID: 18995215
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adipocytokines and cytokeratin-18 in patients with nonalcoholic fatty liver disease: Introduction of CHA index.
    Polyzos SA; Kountouras J; Papatheodorou A; Katsiki E; Patsiaoura K; Zafeiriadou E; Papadopoulou E; Zavos C; Terpos E
    Ann Hepatol; 2013; 12(5):749-57. PubMed ID: 24067262
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated serum levels of caspase-cleaved cytokeratin 18 (CK18-Asp396) in patients with nonalcoholic steatohepatitis and chronic hepatitis C.
    Yilmaz Y; Dolar E; Ulukaya E; Akgoz S; Keskin M; Kiyici M; Yerci O; Oral AY; Gul CB; Gurel S; Nak SG; Gulten M
    Med Sci Monit; 2009 Apr; 15(4):CR189-93. PubMed ID: 19333204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis (NASH) and NASH cirrhosis.
    Alkhouri N; Johnson C; Adams L; Kitajima S; Tsuruno C; Colpitts TL; Hatcho K; Lawitz E; Lopez R; Feldstein AE
    PLoS One; 2018; 13(8):e0202226. PubMed ID: 30161179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Value of serum osteoprotegerin in noninvasive diagnosis of nonalcoholic steatohepatitis].
    Yang M; Liu Y; Zhou G; Guo X; Zou S; Liu S; Jiang L; Liu Y; Zhu L; Guo C; Zhao J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):96-101. PubMed ID: 26983475
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Histopathological findings of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Kage M; Aishima S; Kusano H; Yano H
    J Med Ultrason (2001); 2020 Oct; 47(4):549-554. PubMed ID: 33136250
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum lipocalin-2 is a potential biomarker for the clinical diagnosis of nonalcoholic steatohepatitis.
    Xu G; Wang YM; Ying MM; Chen SD; Li ZR; Ma HL; Zheng MH; Wu J; Ding C
    Clin Mol Hepatol; 2021 Apr; 27(2):329-345. PubMed ID: 33465844
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninvasive diagnostic criteria for nonalcoholic steatohepatitis based on gene expression levels in peripheral blood mononuclear cells.
    Kado A; Tsutsumi T; Enooku K; Fujinaga H; Ikeuchi K; Okushin K; Moriya K; Yotsuyanagi H; Koike K
    J Gastroenterol; 2019 Aug; 54(8):730-741. PubMed ID: 30830270
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease.
    Malik R; Chang M; Bhaskar K; Nasser I; Curry M; Schuppan D; Byrnes V; Afdhal N
    J Gastroenterol Hepatol; 2009 Apr; 24(4):564-8. PubMed ID: 19378390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Performance of Serum microRNAs -122, -192 and -21 as Biomarkers in Patients with Non-Alcoholic Steatohepatitis.
    Becker PP; Rau M; Schmitt J; Malsch C; Hammer C; Bantel H; Müllhaupt B; Geier A
    PLoS One; 2015; 10(11):e0142661. PubMed ID: 26565986
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Validation of the non-alcoholic fatty liver disease activity score.
    Hjelkrem M; Stauch C; Shaw J; Harrison SA
    Aliment Pharmacol Ther; 2011 Jul; 34(2):214-8. PubMed ID: 21585409
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.